Compare Mesoblast Limited (MESO) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Nutanix Inc — how do they compare? Mesoblast Limited trades at $14.31 (market cap $1.75B), while Nutanix Inc trades at $73.81 (market cap $19.78B). The key difference: Nutanix Inc is far larger — about 11.3× Mesoblast Limited's market cap, and Nutanix Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Nutanix Inc for 17 Days on average.
| MESO | NTNX | |
|---|---|---|
Market Cap | $1.75B | $19.78B |
Volume | 239,027 | 1,717,619 |
Sector | Health | Technology |
52-Week High | $20.96 | $73.42 |
52-Week Low | $13.19 | $34.41 |
Typical Hold Time | 14 Days | 17 Days |
Enterprise Value | $1.83B | $18.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Nutanix (NTNX) trades at $73.24, down slightly by 0.25% today, but maintains a bullish technical outlook with strong analyst support. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49, and impressive profitability with an 86.8% gross margin. Recent Gartner Magic Quadrant recognitions highlight competitive strength in virtualization and container management platforms, supporting positive market sentiment.
The investment outlook remains positive with a consensus price target of $76.11 representing 4% upside potential. Key opportunities include external storage partnerships and AI growth initiatives, while risks involve high valuation multiples (EV/EBITDA of 46.22) and negative ROE of -395.76%. Institutional ownership trends and 62.5% analyst buy ratings suggest continued Wall Street confidence in the company's execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
